A new generation of allergy treatments is offering hope to millions of hay fever sufferers, with allergic rhinitis showing promising advances not only in symptom relief but also in long-term prevention.
Hay fever, which affects over 400 million people worldwide, can lead to chronic respiratory issues, ear infections, and even asthma. Experts note that the condition is often underestimated, with many patients receiving only temporary relief rather than preventative care.
Allergen immunotherapy (AIT), administered via sublingual tablets or injections, gradually desensitises the immune system to allergens such as grass, ragweed, or dust mites. Daily sublingual tablets, started 8–16 weeks before allergy season and continued for three years, can significantly reduce symptoms and may even prevent the development of asthma in children. Clinical trials indicate long-term benefits that last for years after treatment ends.
For patients unable to undergo immunotherapy or with severe asthma, biologic therapies provide an alternative, targeting the immune system to reduce inflammation. While effective, biologics are costly and do not typically provide lasting remission.
Other strategies to manage hay fever include nasal sprays combining antihistamine and corticosteroid, second-generation oral antihistamines, and reducing exposure to pollen through measures such as keeping windows closed, using air purifiers, wearing masks outdoors, and showering before sleep.
Experts stress that hay fever should not be trivialised. With effective, safe, and increasingly accessible treatments available, early intervention can greatly improve patients’ quality of life.
Source: BBC
Bd-pratidin English/ Jisan
